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The management of pulmonary tuberculosis (TB) in Scotland in 1993 was studied by asking the physicians 
responsible for all 321 adult cases of the disease notified that year to complete a standardized questionnaire relating 
to drug treatment and bacteriology. The response rate to the questionnaire was 100%. Isoniazid and rifampicin were 
used together in initial therapy in 98.4% of cases, while pyrazinamide was prescribed in 90.3% of cases, broadly in 
keeping with existing treatment guidelines. However, considerable variability was observed both in the drug 
regimens employed, and in the duration of initial and continuation phases of chemotherapy. Treatment regimens 
were therefore frequently at variance with published recommendations. Among patients prescribed drug regimens 
other than those recommended satisfactory completion of therapy was less common. Microbiological confirmation 
was provided for 84% of cases in which clinical samples were submitted. However, in approximately 11% of cases, 
no clinical samples were submitted. Closer adherence to existing treatment guidelines and more rigorous pursuit of 
microbiological confirmation should further improve the overall management of pulmonary TB in Scotland. 
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Introduction 
In 1990 the British Thoracic Society (BTS) published 
recommendations for the treatment of pulmonary tubercu- 
losis (TB) (1). These were based on evidence generated from 
important clinical trials (2-6), and proposed that isoniazid 
(H), rifampicin (R) and pyrazinamide (Z) be used together 
in the initial 2 months, to be followed by isoniazid and 
rifampicin together for a further 4 months continuation 
therapy (1). 
The extent to which these recommendations have been 
implemented in Scotland has not been formally assessed. 
The Scottish Respiratory Tuberculosis (SRTB) Survey pub- 
lished comprehensive data relating to the clinical manage- 
ment of pulmonary TB between 1977 and 1985 (7). Among 
several interesting findings, the Survey noted that ethambu- 
to1 (E) was far more commonly used as part of initial 
therapy in the early 1980s than was pyrazinamide though 
the latter was gaining in popularity (7). 
We aimed to determine how widely the BTS guidelines 
have been adopted in Scotland by examining data pertain- 
ing to treatment of pulmonary TB in adults in Scotland in 
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1993. We also sought to examine whether changes in 
treatment or microbiological information had emerged 
when compared to historical data from the 1980s (7). 
Methods 
The Consultant in Public Health Medicine for each of 
Scotland’s Health Board areas (to whom notifications of 
TB are made) kindly supplied us with details of all notified 
cases of TB in 1993. The named specialist physician respon- 
sible for each case was sent a standardized questionnaire 
designed to determine details of the initial and continuation 
therapy used, and to establish microbiological details. 
Questions asked in the questionnaire are presented in the 
Appendix. In all cases microbiological information was 
derived from reports issued by the local microbiology 
laboratory, together with identification and sensitivity test- 
ing of Mycobacterium tuberculosis cultures by the Scottish 
Mycobacteria Reference Laboratory, which also acted as 
the primary laboratory for the Lothian region. 
Several items in the questionnaire were identical to 
questions posed in previous SRTB Surveys, allowing broad 
comparisons to be made with data generated up to 1985. 
The response rate to the questionnaire was 100%. 
The derivation of the patient groups studied is illustrated 
in Fig. 1. In total 369 patients were diagnosed as having TB 
confined solely to the lungs (as detailed in 8). Eighteen were 
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369 patients notified with pulmonary TB 
I_ 18 under age of 15 
30-no information on treatment regimen 
321 with information pertaining to initial chemotherapy 
32 died before continuation therapy started 
ZO-insuffkient information regarding 
continuation therapy 
3 lost to follow-up 
266 with information pertaining to continuation chemotherapy 
FIG. 1. Derivation of the patient groups studied. 
under 15 years of age and were excluded from analysis. In 
30 of the remaining patients no information relating to 
treatment was available; in 12 of these the diagnosis of 
pulmonary TB was made after death, one left the country, 
and no treatment details were provided for the remaining 
17. In keeping with data presented by other groups (7,9) 
these patients were excluded from analysis, leaving a popu- 
lation of 321 adult patients with a diagnosis of pulmonary 
TB for whom detailed information was available. 
Information pertaining to initial chemotherapy was 
available for all 321 patients. However, no data were 
generated relating to continuation therapy in 55 cases - 32 
died before continuation treatment was considered, insuffi- 
cient information was available to determine details of 
continuation treatment in 20 and three were lost to follow- 
up. Information on continuation treatment was therefore 
available for 266 patients (Fig. 1). 
Patient details were coded numerically to ensure 
confidentiality, and stored in a computerized registry. 
Results 
PATIENTS 
The median age of the patients was 62 years (range 15-92 
years). Two hundred and eighty-seven patients (89.4%) 
were Caucasian. The ethnic origin of the remaining patients 
was as follows, Indian sub-continent in 27 (8.4%), African 
continent in 6 (1.9%), and Chinese sub-continent in one. 
THERAPY 
Initial therapy 
The frequency of use of individual drugs in initial therapy is 
shown in Table 1. The combination of isoniazid and 
rifampicin comprised part of initial therapy in 316 patients 
TABLE 1. Frequency with which individual drugs were used 
in the initial phase of chemotherapy. A total of 321 patients 
received initial phase treatment 
n % 
Isoniazid 317 98.8 
Rifampicin 316 98.4 
Pyrazinamide 290 90.3 
Ethambutol 63 19.6 
Streptomycin 4 1.2 
Ciprofloxacin 3 0.9 
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FIG. 2. Duration of the initial phase of treatment in 
patients prescribed the HRZ/HR regimen (H, isoniazid; 
R, rifampicin; Z, pyrazinamide). ns, Not stated. 
(984%). The use of at least three drugs in initial treatment 
was recorded in 307 patients (956%). 
The duration of initial treatment was extremely variable. 
This is exemplified by the duration of initial treatment 
prescribed for patients receiving isoniazid, rifampicin and 
pyrazinamide as initial therapy, followed by isoniazid and 
rifampicin as continuation therapy (the HRZ/HR regimen) 
shown in Fig. 2. Of the 171 patients receiving HRZlHR for 
whom information was available, 103 (60.2%) received the 
recommended 8 or 9 weeks of initial treatment. However, 
11 patients (6.4%) received less than 8 weeks of HRZ, and 
57 (33.3%) were prescribed more than 9 weeks of HRZ, of 
whom 18 (10.4%) were not switched to HR continuation 
treatment until after 12 weeks. A similar pattern was 
observed for the other treatment regimens employed (data 
not shown). 
Continuation therapy 
The frequency with which individual drugs were used in 
continuation therapy is shown in Table 2. The combination 
PULMONARYTB INSCOTLAND 1~1993 1291 
TABLE 2. Frequency with which individual drugs were used 
in the continuation phase of chemotherapy. A total of 266 
patients received continuation phase treatment 
n % 
Isoniazid 255 95.9 
Rifampicin 249 93.6 
Pyrazinamide 19 7.1 
Ethambutol 28 10.5 
Streptomycin 3 I.1 
Ciprofloxacin 3 1.1 
- 
HRZ/HR HRZE/HR HRE/HR X/E Other 
FIG. 3. Distribution of drug regimens prescribed to 
patients receiving initial and continuation chemotherapy, 
n=266. x/E, Drug regimen in which ethambutol featured 
in continuation therapy. All other abbreviations are as 
explained in text. 
of isoniazid and rifampicin alone was used in continuation 
in 221 cases (83.1%) for which information was available, 
while a further 19 patients (7.1%) received these drugs in 
combination with others. 
Continuation therapy could be broadly divided accord- 
ing to individual drugs prescribed, giving rise to five groups, 
namely HRZ/HR; HRZE/HR; HRE/HR; treatments in 
which ethambutol featured as part of continuation therapy; 
and other miscellaneous treatments. The proportion of 
patients in each group is shown in Fig. 3. A high proportion 
of patients in each group was treated for longer than the 
recommended 6-month period (as illustrated in Fig. 4, 
using the example of patients completing treatment with 
the recommended HRZ/HR regimen), while a minority 
received treatment for less than 6 months. 
The attending physician considered that chemotherapy 
was completed as planned in 135 (78.5%) of the patients 
prescribed the recommended HRZ/HR regimen. Of the 
remaining 37 patients 13 were still receiving some form of 
chemotherapy 1 year after diagnosis, 13 died during treat- 
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FIG. 4. Total duration of chemotherapy in patients 
prescribed the HRZlHR regimen (H, isoniazid; 
R, rifampicin; Z, pyrazinamide). 
ment, five were lost to follow-up, two were non-compliant 
with treatment, and incomplete information was available 
on the final four. Satisfactory completion of treatment was 
achieved in a lower proportion of patients when other 
treatment regimens were employed: 67.7% for those receiv- 
ing HRZE/HR, 75.0% for those receiving HRE/HR, 42.9% 
for the group receiving ethambutol in continuation, and 
45.8% for the group receiving other regimens. In total 193 
patients (60.1%) among the total population of 321 were 
considered to have completed treatment as planned. 
Sixty-two patients died within 1 year of the diagnosis of 
pulmonary TB. The mean age of this group of patients was 
71.3 years. The majority of deaths were considered to be 
unrelated to TB. TB was considered to be a primary cause 
of death in 17 of these patients, for whom the mean age was 
71.5 years. Detailed information was available for 10 of 
these 17 patients. Six had received anti-tuberculous chemo- 
therapy for between 5 and 11 days before death and two 
had received prolonged, non-standard regimens. 
Among patients in whom chemotherapy was completed 
18 (9.3%) were said to have required a modification of 
treatment because of drug toxicity. 
MICROBIOLOGY 
In 36 cases (11.2%) no microbiological samples were 
received, and in 11 cases (3.4%) no data regarding micro- 
biology were available, leaving detailed information for 
274 cases. Mycobacteriurn tuberculosis was identified on 
both sputum smear and culture in 139 cases (50.8%), on 
culture alone in 66 cases (24.1%), and by sputum smear 
alone in 25 cases (9.1%). In total bacteriological confirma- 
tion by smear and/or culture was obtained for 230 patients 
(83.9%) from whom samples were sent. In the remaining 44 
cases (16.1%) samples were sent but no bacteriological 
confirmation was obtained. The rate of microbiological 
confirmation was higher in patients receiving recommended 
chemotherapeutic regimens than in those prescribed 
non-standard regimens. 
Drug sensitivity results were available to the attending 
physician in 194 of the 205 culture positive cases (94.6%). 
Isoniazid resistance was reported in 12 cases and rifampicin 
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resistance in six (representing 5.7% and 2.9% of cases in 
which information was available, respectively). No cases 
of combined isoniazid and rifampicin resistance were 
identified. 
Discussion 
These data indicate that since the publication of BTS 
recommendations for the management of pulmonary TB 
(1) there has been a considerable rise in the use of pyrazi- 
namide as part of initial therapy in Scotland (from approxi- 
mately 35% of cases in 1985 to around 90% in 1993) with a 
reduction in the administration of ethambutol (92% in 1985 
compared with 20% in 1993). These findings are in keeping 
with the increased use of pyrazinamide in England and 
Wales (9,lO). However, the prescription of pyrazinamide 
was already increasing steadily prior to the publication of 
the BTS recommendations (7,9). The combination of isoni- 
azid and rifampicin remained the backbone of both initial 
and continuation treatment. 
The continued use of ethambutol in 20% of initial therapy 
may reflect a preference on the part of some physicians 
to cover the possibility of drug resistance or atypical myco- 
bacteria while awaiting culture and sensitivity results. BTS 
recommendations suggest incorporating ethambutol where 
isoniazid resistance is suspected (1). Our data suggests an 
approximate rate of isoniazid resistance of 6% while almost 
20% of patients received ethambutol in initial therapy. 
Reasons for the high prevalence of ethambutol prescription 
in continuation therapy remain unclear. 
Several comparisons can be made between elements of 
our data and information generated in Scotland in 1985 by 
the SRTB survey (7) and in England and Wales in 1988 
and 1993 (9,lO). It should be noted however that there were 
small differences in the composition of cases included in 
these studies. The SRTB survey, unlike this study, included 
only patients admitted to hospital as part of pulmonary TB 
management, and among this number included 5% of 
patients under the age of 15. The BTS study in England and 
Wales differed from this study in that 36% of patients were 
non-Caucasian and that patients with no known bacterio- 
logical results were excluded from final analysis. However, 
allowing for these small differences broad comparisons can 
be made. 
A high proportion of patients received chemotherapy for 
longer than 6 months in Scotland in 1993. This was largely 
attributable to prolongation of the initial phase of treat- 
ment. A similar pattern emerged in England and Wales in 
1988 (9). A continued tendency to prescribe 9 months of 
chemotherapy partly explained the prolonged mean dura- 
tion of treatment in England and Wales, but this accounted 
for few cases in Scotland. 
Our findings indicate that treatment was completed as 
intended by the attending physician in only 60% of cases. 
This compares with a corresponding figure of 59.3% in 1985 
(7). Approximately 58% of patients completed therapy as 
planned in England and Wales in 1988 (9). 
The proportion of patients with pulmonary TB who died 
within 1 year of treatment was higher in 1993 (16.8%) than 
in 1985 (13.5%). However, a higher proportion of those 
who died in the 1993 survey were over the age of 65 (data 
not shown) and it seems likely that the increased death rate 
simply reflects the more elderly age distribution. The pro- 
portion of deaths in which TB was considered a primary 
cause was higher than in England and Wales (9). Interest- 
ingly, in the few cases in which detailed information was 
available there was a distinct trend for deaths attributable 
to TB to occur early in the course of treatment. This might 
imply that technologies allowing earlier diagnosis and treat- 
ment (11) may reduce mortality attributable to TB. An 
alternative inference might be that extra vigilance is 
required in elderly patients newly diagnosed, and treated, 
for pulmonary TB. 
The incidence of recorded drug toxicity necessitating 
modification of therapy was lower (go/o) than that in 
England and Wales (14%) (9). A possible explanation for 
this observation is under-reporting of drug reactions 
by patients andlor physicians. The current study did not 
allow for an assessment of whether toxicity contributed to 
mortality. 
The percentage of patients in whom bacteriological con- 
firmation was obtained via sputum smear and/or culture 
was almost identical to that observed in Scotland in 1985, 
and slightly higher than in 1983 and 1984 (7). Despite the 
high rate of microbiological confirmation, the diagnosis of 
TB was apparently made in the absence of any clinical 
samples being submitted in over 10% of patients. This 
compares with a rate of approximately 5% in the 1980s. 
Furthermore, a high proportion of cases proved to be 
culture positive but sputum-smear negative, or sputum- 
smear positive and culture negative, while in 44 cases 
samples were sent but no bacteriological confirmation was 
possible. The absence of concomitantly positive smear and 
culture results may reflect laboratory techniques, insuffi- 
cient or technically inadequate clinical sampling, or the 
coincidental use of treatments that might clear M. tubeucu- 
losis in clinical samples (e.g. ciprofloxacin or aminoglyco- 
sides). In cases where no bacteriological confirmation could 
be obtained an alternative possibility could have been 
diagnostic inaccuracy. Where possible clinical samples of 
high quality should be sent for bacteriological confirma- 
tion, not least to prevent emergence of multi-drug resistance 
in Scotland (12). 
Taken together, these data illustrate that the rate of 
satisfactory completion of treatment, and the rate of micro- 
biological confirmation were no different from rates 
recorded in Scotland 8 years previously. There has been 
some movement toward adoption of the drug regimens 
recommended in published guidelines, but major obstacles 
still lie in the way of their widespread application. Principal 
among these are trends for prolonged duration of treatment 
regimens, continued use of non-standard regimens, and 
frequent cases in which no clinical samples are sent to the 
laboratory. Closer adherence to existing guidelines, and 
increased pursuit of microbiological confirmation appear 
not only to be practicable, but also highly desirable given 
that less satisfactory completion of therapy and lack of 
laboratory data were associated with non-standard drug 
regimens in this study. 
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Appendix 
QUESTIONNAIRE USED 
Date of birth 
Site of disease 
Date of notification or commencement of treatment 
(whichever was first) 
Initial treatment regimen 
Was chemotherapy initiated for treatment of TB? Yes/no 
Date chemotherapy commenced 
Which of the following were used in initial therapy? 
isoniazid, rifampicin, ethambutol, pyrazinamide, strepto- 
mycin, PAS, ethionamide, cycloserine, capreomycin, 
viomycin, other (please state) 
What was duration of initial treatment regimen in weeks? 
Continuation phase regimen 
Was initial therapy followed by a continuation phase of 
chemotherapy? Yes/no 
if yes, state date commenced 
if no, state reason 
Which of the following drugs were used as continuation 
therapy? 
isoniazid, rifampicin, ethambutol, pyrazinamide, strepto- 
mycin, PAS, ethionamide, cycloserine, capreomycin, 
viomycin, other (please state) 
Was chemotherapy continuing 1 year after notification/start 
of treatment? Yes/no 
if no, give date treatment ended or date patient died 
If chemotherapy not continuing 1 year after notification/ 
start of treatment, had patient died within the 
year? Yes/no 
if yes, give date of death, and give cause of death in 
opinion of physician from the following - TB primary 
cause, TB secondary cause, late effects of TB, death not 
related to TB. 
If chemotherapy not continuing 1 year after notification/ 
start of treatment, was treatment completed as 
planned? Yes/no 
If no, state reason from the following list -patient 
stopped treatment, physician stopped treatment, patient 
lost to follow-up, patient died, other (please specify) 
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If chemotherapy was completed as planned were there any 
modifications in treatment regimen after initial chemo- 
therapy was commenced? Yeslno 
If yes, state reason for modification from the following 
list - drug toxicity, initial drug resistance, bacteriological 
relapse during therapy, bacteriological relapse on stop- 
ping therapy, default by patient, other (please specify) 
Bacteriology 
State laboratory used for initial bacteriological con- 
firmation from the following list - Scottish Mycobacteria 
Reference Laboratory, local laboratory, both, no 
bacteriology 
Was disease confirmed bacteriologically? Yes/no 
if yes, was disease confirmed with positive smear? 
Yes/no 
was disease confirmed with positive culture? 
Yes/no 
From the following list state drugs tested for sensitivity, 
and for each state whether organism sensitive or resistant 
isoniazid, rifampicin, ethambutol, pyrazinamide, strepto- 
mycin, PAS, ethionamide, cycloserine, capreomycin, 
viomycin, other (please specify) 
